PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 178 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2018. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $194,000 | -32.9% | 27,735 | -12.0% | 0.02% | -37.5% |
| Q2 2021 | $289,000 | +112.5% | 31,530 | +134.6% | 0.02% | +166.7% |
| Q3 2020 | $136,000 | -79.6% | 13,441 | -83.0% | 0.01% | -81.2% |
| Q1 2020 | $667,000 | +152.7% | 79,050 | +161.9% | 0.05% | +200.0% |
| Q4 2019 | $264,000 | -49.4% | 30,187 | -37.8% | 0.02% | -64.4% |
| Q3 2019 | $522,000 | -79.4% | 48,506 | -25.9% | 0.04% | -75.0% |
| Q1 2019 | $2,538,000 | +125.6% | 65,430 | +166.7% | 0.18% | +111.8% |
| Q3 2018 | $1,125,000 | +78.0% | 24,529 | +164.3% | 0.08% | +93.2% |
| Q1 2018 | $632,000 | +149.8% | 9,281 | +220.0% | 0.04% | -36.2% |
| Q2 2017 | $253,000 | -57.3% | 2,900 | -85.0% | 0.07% | -26.6% |
| Q4 2016 | $593,000 | -46.2% | 19,326 | +17.6% | 0.09% | -61.8% |
| Q3 2016 | $1,102,000 | +15.2% | 16,429 | -49.6% | 0.25% | +119.6% |
| Q1 2016 | $957,000 | -24.8% | 32,600 | +92.9% | 0.11% | +1.8% |
| Q3 2015 | $1,273,000 | +356.3% | 16,900 | +604.2% | 0.11% | +254.8% |
| Q2 2015 | $279,000 | – | 2,400 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |